The mechanism of action responsible for the motor depressant effects of cannabinoids,
which operate through centrally expressed cannabinoid CB 1 receptors, is still a matter of …

Despite the profound effect of cannabinoids on motor function, and their therapeutic
potential in Parkinson's and Huntington's diseases, the cellular and subcellular distributions …

One of the prominent pharmacological features of drugs acting at the brain cannabinoid
receptor (CB1) is the induction of alterations in motor behavior. Catalepsy, immobility, ataxia …

Cannabinoids produce a number of central nervous system effects via the CB 2 receptor (CB
2 R), including analgesia, antianxiety, anti-reward, hypoactivity and attenuation of opioid …

At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is
rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can …

CB1 cannabinoid receptors in the neostriatum mediate profound motor deficits induced
when cannabinoid drugs are administered to rodents. Because the CB1 receptor has been …

The levels of CB1 cannabinoid receptors in the basal ganglia are the highest in the brain,
comparable to the levels of dopamine receptors, a major transmitter in the basal ganglia …

Several lines of evidence indicate that cannabinoids, among other functions, are involved in
motor control. Although cannabinoid receptors (CB1) mRNA has been observed in medium …

The introduction of two concepts,“local module” and “receptor heteromer”, facilitates the
understanding of the role of interactions between different neurotransmitters in the brain. In …

Adenosine A2A receptor antagonists are psychomotor stimulants that also hold therapeutic
promise for movement disorders. However, the molecular mechanisms underlying their …